Case Control Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 21, 2021; 27(23): 3357-3371
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3357
Table 1 Characteristics of the study groups at the time of magnetic resonance imaging
Characteristic
Healthy controls (n = 30)
T2DM (n = 30)
NODAP (n = 30)
P value1
Age (yr)50.0 (36.5-68.8)55.5 (41.8-66.3)58.5 (48.5-67.3)0.213
Men, n (%)21 (70.0)21 (70.0)21 (70.0)1.000
Body mass index (kg/m2)24.0 (21.8-28.1)30.3 (26.4-35.4)27.5 (24.1-32.7)< 0.001
Waist-height ratio0.5 (0.5-0.5)0.6 (0.5-0.6)0.6 (0.5-0.6)< 0.001
Triglycerides (mmol/L)1.0 (0.6-1.2)1.7 (1.3-3.7)2.2 (1.3-3.6)0.035
Total cholesterol (mmol/L)4.5 (3.4-5.6)5.1 (3.9-5.8)5.1 (4.1-5.7)0.388
HDL cholesterol (mmol/L)1.2 (0.8-1.8)1.2 (0.9-1.4)1.2 (1.1-1.4)0.680
LDL cholesterol (mmol/L)2.7 (2.0-3.4)2.7 (1.6-3.3)2.6 (2.1-3.5)0.542
Fasting insulin (mIU/L)11.8 (4.8-16.6)12.2 (8.2-17.2)13.3 (7.4-18.3)0.523
HOMA-IR (mIU/L·mmol/L)2.8 (1.2-3.3)3.3 (2.1-5.1)3.3 (1.9-5.3)0.244
Smoking status20 (0-1)0 (0-1)1 (0-1)0.016
Alcohol consumption (g/wk)39 (4.5-96)12 (6-144)12 (0-108)0.279
Amylase (U/L)29.0 (20.2-33.9)20.2 (14.0-31.5)28.7 (19.4-33.3)0.158
Lipase (pg/mL)7.2 (5.5-8.7)7.6 (5.9-10.5)6.5 (5.5-8.6)0.340
Chymotrypsin (U/L)6.2 (5.2-7.1)4.6 (2.9-6.7)5.9 (4.9-6.6)0.314
Table 2 Differences in abdominal fat phenotypes between the study groups
Fat phenotype
Overall1
T2DM vs NODAP
T2DM vs healthy controls
NODAP vs healthy controls
Intra-pancreatic fat (%)
Model 1< 0.0010.290< 0.0010.001
Model 2 0.0020.5550.0010.004
Model 30.0010.4400.0010.001
Model 40.0030.1870.0020.012
Liver fat (%)
Model 10.4160.8060.3220.211
Model 2 0.6810.4570.9830.465
Model 30.5560.9980.3930.312
Model 40.6120.4280.3290.801
Skeletal muscle fat (%)
Model 10.3480.1480.5160.420
Model 2 0.3290.1370.4550.489
Model 30.5850.3190.6920.544
Model 40.4770.2430.5510.460
Visceral fat (cm3)
Model 1< 0.0010.093< 0.0010.001
Model 2 0.0100.5960.0050.012
Model 30.0010.249< 0.0010.003
Model 40.0050.7870.0120.003
Subcutaneous fat (cm3)
Model 10.0130.2140.0030.082
Model 2 0.7400.4880.5080.987
Model 30.0380.2450.0120.081
Model 40.0340.0630.0090.301
Table 3 Associations between abdominal fat phenotypes and pancreatic enzymes
Fat phenotypeHealthy
T2DM
NODAP

β
S.E.
P value
β
S.E.
P value
β
S.E.
P value
Intra-pancreatic fat (%)
Pancreatic amylase-0.8322.2200.7120.5731.7090.741-2.2010.8990.023
Pancreatic lipase 0.2580.4210.546-0.6310.3970.8761.3431.4620.367
Chymotrypsin-0.1370.1790.452-0.5790.6100.3430.1640.2700.550
Liver fat (%)
Pancreatic amylase0.6850.4440.140-0.0220.1570.890-0.4930.3310.151
Pancreatic lipase -0.1360.0890.141-0.1340.3510.709-0.0980.2800.730
Chymotrypsin0.0020.0400.967-0.0710.0690.3140.0590.0510.259
Skeletal muscle fat (%)
Pancreatic amylase-0.5700.5950.351-0.2410.4740.619-0.1850.1250.151
Pancreatic lipase 0.1950.0930.047-1.3450.9120.161-0.0710.4460.875
Chymotrypsin-0.0230.0440.609-0.1290.1050.238-0.0140.0860.868
Visceral fat (cm3)
Pancreatic amylase0.0020.0050.6640.0000.0020.841-0.0040.0020.028
Pancreatic lipase -0.5880.8390.490-3.2470.4620.4930.5330.2500.833
Chymotrypsin-0.3140.3620.3940.2870.5660.6190.2400.4580.606
Subcutaneous fat (cm3)
Pancreatic amylase0.0030.0020.2240.0000.0020.821-0.0020.0010.232
Pancreatic lipase -0.5730.4820.246-2.0323.4440.564-0.0361.9310.985
Chymotrypsin-0.0300.2150.890-0.5270.5340.338-0.0910.3500.797